Dose escalation studies of ara-c (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years:: Final induction results of CALGB 9621.

被引：0
|
作者：
Kolitz, JE [1 ]
George, SL [1 ]
Dodge, RK [1 ]
Hoke, E [1 ]
Hurd, DD [1 ]
Powell, BL [1 ]
Velez-Garcia, E [1 ]
Caligiuri, MA [1 ]
Moore, JO [1 ]
Vardiman, JW [1 ]
Bloomfield, CD [1 ]
Larson, RA [1 ]
机构：
[1] Canc & Leukemia Grp B, Chicago, IL USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1928
引用
收藏
页码：461A / 461A
页数：1
相关论文
共 7 条
  • [1] Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621
    Kolitz, JE
    George, SL
    Dodge, RK
    Hurd, DD
    Powell, BL
    Allen, SL
    Velez-Garcia, E
    Moore, JO
    Shea, TC
    Hoke, E
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4290 - 4301
  • [2] Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old:: Preliminary results of CALGB 9621.
    Kolitz, JE
    George, SL
    Hurd, D
    Hoke, E
    Dodge, RK
    Velez-Garcia, E
    Powell, BL
    Moore, J
    Caligiuri, MA
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 384A - 384A
  • [3] Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALGB 9720).
    Baer, MR
    George, SL
    Dodge, RK
    Cooke, K
    Caligiuri, MA
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 1999, 94 (10) : 383A - 383A
  • [4] A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.
    Lee, E
    George, S
    Caligiuri, M
    Dodge, R
    Smith, R
    Szatrowski, T
    Schiffer, C
    [J]. BLOOD, 1997, 90 (10) : 2256 - 2256
  • [5] Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia (AML) patients ≥ 60 years old:: Correlation of outcome with functional MDR (CALGB studies 9720 and 9760).
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2001, 98 (11) : 461A - 462A
  • [6] Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420
    Lee, EJ
    George, SL
    Caligiuri, M
    Szatrowski, TP
    Powell, BL
    Lemke, S
    Dodge, RK
    Smith, R
    Baer, M
    Schiffer, CA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2831 - 2839
  • [7] A Randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using P-Glycoprotein (Pgp) modulation with valspodar (PSC833):: Preliminary results of cancer and leukemia group B study 19808.
    Kolitz, JE
    George, SL
    Marcucci, G
    Vij, R
    Powell, BL
    Allen, SL
    De Angelo, DJ
    Shea, T
    Stock, W
    Hars, V
    Hoke, E
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2005, 106 (11) : 122A - 123A
1